Monday , July 16 2018
Home / Production Assistant, Diabetes In Control (page 34)

Production Assistant, Diabetes In Control

Achieving A1C Target

Test Your Knowledge

Your patient has been taking metformin, glipizide, and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he has not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: A. tend to lower A1c to a larger degree. B. are associated with less weight gain. C. cause less hypoglycemia. D. are a good option for people with irregular meal schedules. Follow the link to see the right answer.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #98: Metabolomics: Applications in Type 2 Diabetes Mellitus and Insulin Resistance Part 4

Future directions and potential application of metabolite profiling in type 2 diabetes: metabolomics approaches have unmasked a variety of metabolic pathways influenced by T2DM or insulin resistance, moving the field of metabolic physiology beyond a “glucocentric” viewpoint of these conditions. However, a difficulty in interpretation is that the fasting concentration of a metabolite only reflects a single moment in time, and etiology or tissue origins of any metabolite differences across comparator groups requires further validation.

Read More »

Pioglitazone Changes

Test Your Knowledge

A 62-year-old Asian-American female arrives at your office for a new patient appointment. Her current medications are metformin, pioglitazone, enalapril, lovastatin, alendronate, calcium supplements and vitamin D. Her A1C is on target at 6.9%, however you decide to replace her pioglitazone with a different antihyperglycemic medication. Why would you make this decision? A. Pioglitazone increases the risk of hypertriglyceridemia B. Pioglitazone increases the risk for cardiovascular events C. Pioglitazone increases the risk for fractures D. Pioglitazone increases the risk for hypoglycemia Follow the link to see the right answer.

Read More »

SGLT-2 as 2nd Drug

Are you open to recommending an SGLT-2 inhibitor as a second drug for a patient with type 2 diabetes who is overweight and has not met their goal? Follow the link to see how you compare to your colleagues.

Read More »

R. Keith Campbell Recognized with Lifetime Achievement Award

Pharmacy innovator Keith Campbell, B.Pharm, MBA, CDE, who sits on our board of advisors at Diabetes in Control, is one of the first pharmacists to become a certified diabetes educator and the inspiration for hundreds of other pharmacists and nurses who since followed in his footsteps, received the Lifetime Achievement Award on Friday, Oct. 20, 2017 at the Washington State University College of Pharmacy Crimson Gala.

Read More »